Cornell researchers have discovered a way to open one of the major barriers to the brain, called the blood brain barrier (BBB), which prevents the entry of therapies to treat brain disorders, such as Alzheimer’s disease.
The finding also has implications for treating all chemotherapy-resistant cancers.
For a century now, a major challenge in the treatment of diseases of the brain has been discovering how to safely deliver drugs across the BBB. The BBB is composed of a layer of specialized cells, called endothelial cells, which line the brain’s blood vessels and safeguard the brain from unwanted substances. These cells also selectively allow entry of molecules needed for brain function, such as amino acids, oxygen, glucose and water.
Cornell researchers report that an FDA-approved drug called Lexiscan, which is used in heart imaging, activates receptors – called adenosine receptors – that are expressed on these BBB cells.
“We can open the BBB for a brief window of time, long enough to deliver therapies to the brain, but not too long so as to harm the brain. We hope in the future, this will be used to treat many types of neurological disorders,” said Margaret Bynoe, associate professor in the Department of Microbiology and Immunology in Cornell’s College of Veterinary Medicine. Bynoe is senior author of the study appearing April 4 in The Journal of Clinical Investigation. Do-Geun Kim, now a postdoctoral associate in Bynoe’s lab, is the paper’s first author.
The researchers were able to deliver chemotherapy drugs into the brains of mice, as well as large molecules, like an antibody that binds to Alzheimer’s disease plaques, according to the paper.
To test whether this drug delivery system has application to the human BBB, the lab engineered a BBB model using human primary brain endothelial cells. They observed that Lexiscan opened the engineered BBB in a manner similar to its actions in mice.
Bynoe and Kim discovered that a protein called P-glycoprotein is highly expressed on brain endothelial cells and blocks the entry of most drugs delivered to the brain. Lexiscan acts on one of the adenosine receptors expressed on BBB endothelial cells specifically activating them. They showed that Lexiscan down-regulates P-glycoprotein expression and function on the BBB endothelial cells. It acts like a switch that can be turned on and off in a time dependent manner, which provides a measure of safety for the patient.
“We demonstrated that down-modulation of P-glycoprotein function coincides exquisitely with chemotherapeutic drug accumulation” in the brains of mice and across an engineered BBB using human endothelial cells, Bynoe said. “The amount of chemotherapeutic drugs that accumulated in the brain was significant.”
In addition to P-glycoprotein’s role in inhibiting foreign substances from penetrating the BBB, the protein is also expressed by many different types of cancers and makes these cancers resistant to chemotherapy.
“This finding has significant implications beyond modulation of the BBB,” Bynoe said. “It suggests that in the future, we may be able to modulate adenosine receptors to regulate P-glycoprotein in the treatment of cancer cells resistant to chemotherapy.”
Because Lexiscan is an FDA-approved drug, ”the potential for a breakthrough in drug delivery systems for diseases such as Alzheimer’s disease, Parkinson’s disease, autism, brain tumors and chemotherapy-resistant cancers is not far off,” Bynoe said.
Another advantage is that these molecules (adenosine receptors and P-glycoprotein are naturally expressed in mammals. “We don’t have to knock out a gene or insert one for a therapy to work,” Bynoe said.
The Latest on: Blood brain barrier
via Google News
The Latest on: Blood brain barrier
- Illustration of the Blood-Brain Barrier (image)on November 12, 2019 at 12:40 pm
This illustration shows the components of the blood-brain barrier, a collection of blood vessels that filters what goes in and out of the brain. The blood-brain barrier is the greatest obstacle when ...
- Liposomes cross blood brain barrier, could get healing drugs to stroke-affected brainon November 7, 2019 at 1:34 pm
A new study from University of Manchester researchers, published in ACS Neuro, shows a high possibility of treating stroke patients using very small cell sacs called liposomes to bypass the blood ...
- Nanoparticles Cross Blood-Brain Barrier to Treat Strokeon November 7, 2019 at 9:55 am
the potential to provide additional drug therapy remains mostly unexplored because of the difficulty in getting medications past the blood-brain barrier. This is a companion discussion topic for the ...
- Selective Liposomal Transport through Blood Brain Barrier Disruption in Ischemic Stroke Reveals Two Distinct Therapeutic Opportunitieson November 6, 2019 at 4:39 pm
Nanomedicine Lab, Faculty of Biology, Medicine and Health, AV Hill Building, The University of Manchester, Manchester M13 9PT, United Kingdom ...
- Dynamic transition of the blood-brain barrier in the development of non-small cell lung cancer brainon October 31, 2019 at 9:12 am
Effective drug delivery through the BTB is one of the greatest therapeutic obstacles in treating brain metastases. Using an experimental model, the researchers defined key changes within the BTB ...
- Blood–brain barrier best breached by small moleculeson October 30, 2019 at 3:38 am
2019.08.024) Usually, the brain is isolated from substances circulating in the bloodstream by the blood–brain barrier (BBB), a semipermeable layer of cells that permits only certain molecules to pass.
- blood-brain barrieron October 23, 2019 at 5:30 am
That’s because the blood-brain barrier would otherwise prevent the drug from reaching Mila’s brain. Beginning in January 2018, she received gradually escalating doses of milasen every two weeks for ...
- Blood Brain Barrier Technologies Market - Industry Insights By Growth, Emerging Trends And Forecast By 2025on October 21, 2019 at 11:09 pm
Oct 22, 2019 (AmericaNewsHour) -- Global Blood Brain Barrier Technologies Market valued approximately USD xxx billion in 2017 is anticipated to grow with a healthy growth rate of more than xxx% over ...
- Drug Delivery Across Blood Brain Barrier Market 2019 Global Industry Analysis and Opportunity Assessment 2025on October 21, 2019 at 8:22 pm
Oct 22, 2019 (Brandessence Market Research via COMTEX) -- Drug Delivery Across Blood Brain Barrier Market unveils a succinct analysis of the market size, regional spectrum and revenue forecast about ...
- Overcoming the blood-brain-barrier: Delivering therapeutics to the brainon October 11, 2019 at 8:54 am
Blood capillaries in the brain are not permeable to many drugs and the majority are excluded from the brain by a protective barrier, called the blood-brain-barrier (BBB), and current treatment options ...
via Bing News